Longs - SP and Bashers with multiple userids, page-25

This is a coherent explanation of ANAVEX 2-73 and the current trial... http://www.anavex.com/?post_type=news&p=1165

"The first part is a scheduled Phase 1b/2a trial of approximately 40 patients who will receive either ANAVEX 2-73 or standard of care (donepezil) with ANAVEX 2-73. The study will explore dose and schedule as well as the efficacy of the combination. Patients in this study will have the option to rollover into a single open-label study in order to further accumulate safety, tolerability and efficacy data.
The second part of the study is designed as a double-blind Phase 2 trial and will randomize AD patients to standard of care (donepezil) or standard of care (donepezil) with ANAVEX 2-73 with a primary outcome measure at 26 weeks efficacy based on standard cognitive measures. All patients from this second study will also have the option to rollover into the single open-label study in order to further accumulate safety, tolerability and efficacy data."

And here's an article about the novel measurement technique being used (anybody else scared for Anavex?) http://alzheimersnewstoday.com/2014...th-neuronetrix-for-alzheimers-clinical-trial/

I hope it goes well for Anavex (more accurately for AD sufferers), but it is clearly very early in what we know to be a long process.